Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Research analysts at Leerink Partnrs dropped their Q4 2025 earnings estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, September 30th. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share. Regeneron Pharmaceuticals Stock PerformanceShares of REGN opened at $562.27 on Wednesday. Regeneron Pharmaceuticals Dividend AnnouncementThe firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Featured StoriesReceive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.